Shares of Anavex Life Sciences Corp (NASDAQ:AVXL) have been given an average rating of “Buy” by the six analysts that are covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $13.00.
Several equities research analysts have issued reports on AVXL shares. BidaskClub raised Anavex Life Sciences from a “sell” rating to a “hold” rating in a research note on Friday, February 14th. ValuEngine upgraded Anavex Life Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, February 4th. Finally, Zacks Investment Research lowered Anavex Life Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Janney Capital Management LLC acquired a new stake in Anavex Life Sciences in the 4th quarter valued at $27,000. Squarepoint Ops LLC acquired a new position in Anavex Life Sciences in the 3rd quarter worth approximately $40,000. FormulaFolio Investments LLC acquired a new position in Anavex Life Sciences in the 3rd quarter worth approximately $44,000. Lionsbridge Wealth Management LLC acquired a new position in Anavex Life Sciences in the 4th quarter worth approximately $39,000. Finally, Kessler Investment Group LLC boosted its stake in Anavex Life Sciences by 418.0% in the 3rd quarter. Kessler Investment Group LLC now owns 20,721 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 16,721 shares during the period. Institutional investors and hedge funds own 22.89% of the company’s stock.
Anavex Life Sciences (NASDAQ:AVXL) last released its earnings results on Thursday, February 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.02. Equities research analysts anticipate that Anavex Life Sciences will post -0.54 earnings per share for the current year.
About Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.
See Also: What does RSI mean?
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.